Earnings · China A-shares
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A (301211) earnings
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A published its Q3 report on 2026-10-26: net profit +89.45% year on year, +2543.79% excluding one-off items. Wave Radar's earnings-quality score is 100 of 100 (Sound). The stock moved -4.90% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-26
- Period end
- 2026-09-30
- Net profit YoY
- +89.45%
- Excl. one-offs YoY
- +2543.79%
- Net profit QoQ
- -54.48%
- Result
- Great
- Quality score
- 100
- Quality
- Sound
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | -5.73% | — |
| 3 days | -4.90% | — |
| 7 days | +1.20% | — |
| 14 days | -1.48% | — |
Report history
Over the last 8 reports, net profit grew year on year in 2 of them. The stock rose in the 3 trading days after 2 of 8 reports (average -0.25%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-27 | ¥39.66M | +89.45% | +2543.79% | +11.14% | 0.09 | 1.74% | -4.90% | — | — |
| 2026 interim report | 2026-08-25 | ¥30.14M | +62.48% | +153.59% | +5.43% | 0.07 | 1.32% | +10.38% | +5.02% | +11.05% |
| 2026 Q1 report | 2026-04-23 | ¥9.22M | -10.73% | +0.24% | +5.00% | 0.02 | 0.40% | -1.86% | -19.24% | -17.68% |
| 2025 annual report | 2026-03-31 | ¥34.91M | -61.87% | -89.19% | +1.67% | 0.08 | 1.53% | +2.81% | -8.33% | -16.75% |
| 2025 Q3 report | 2025-10-28 | ¥20.93M | -71.96% | -99.14% | -4.52% | 0.05 | 0.92% | -2.93% | +2.20% | +5.57% |
| 2025 interim report | 2025-08-01 | ¥18.55M | -72.92% | -93.21% | -2.93% | 0.06 | 0.80% | -1.18% | -34.16% | -46.20% |
| 2025 Q1 report | 2025-04-28 | ¥10.33M | -72.38% | -93.03% | -17.10% | 0.02 | 0.45% | -1.97% | +14.17% | +10.93% |
| 2024 annual report | 2025-04-24 | ¥91.55M | -48.02% | -57.14% | -32.75% | 0.22 | 3.94% | -2.33% | +14.62% | +12.35% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.